Ensartinib after chemotherapy and radiation for stage III ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a pill called ensartinib after you finish chemotherapy and radiation for stage III ALK-positive lung cancer. It may help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have stage III lung cancer (non-small cell) that cannot be treated with surgery.
- Your cancer has a change in the ALK gene (called ALK-positive).
- You have just finished a standard course of chemotherapy plus radiation, and your cancer has not grown or spread.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
Hear when a new Ensartinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.